Broncus Holding Company (“Broncus”), a global leader in diagnostic and therapeutic technology for lung diseases, today announced the closing of a Series C round of funding led by Lake Bleu Capital, and including Baidu Capital, the venture arm of one of the world’s largest Internet and data science companies, Ascendum Capital, CNCB Capital and DCP Capital, along with previous investor Qiming Venture Capital.


Broncus is dedicated to the development of diagnostic and therapeutic technology for lung disease. Founded in 2012, the company’s primary technology platforms focus on the diagnosis of lung cancer and the treatment of emphysema. Its lung cancer portfolio includes the Archimedes® System, Archimedes® Planner, LungPoint® Virtual Bronchoscopic Navigation (VBN) System, LungPoint® Planner and FleXNeedle®.

Broncus Holding Company Closes Series C Financing

Description

Company Information

FundzWatch™ Score

Buyer Intent Analysis

Broncus Holding Company Closes Series C Financing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

FundzWatch™ Score

Buyer Intent Analysis

Company Information